Novo Nordisk's Wegovy approved in the US for the treatment of MASH
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Reinforcing commitment to ethical and sustainable growth
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
This is the group’s first NoC approval in Canada
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Subscribe To Our Newsletter & Stay Updated